

CERUS CORP  
Form 8-K  
February 03, 2005

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **February 2, 2005**

## CERUS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-21937**  
(Commission File No.)

**68-0262011**  
(IRS Employer Identification No.)

**2411 Stanwell Drive**  
**Concord, California 94520**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 288-6000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: CERUS CORP - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Definitive Material Agreement.**

On February 2, 2005, Cerus Corporation (the Company) entered into an agreement with subsidiaries of Baxter International Inc. (Baxter) which restructures the terms of their collaboration with respect to the INTERCEPT Blood System and resolves the loan dispute between the parties. A copy of the joint press release issued by the Company and Baxter, entitled Baxter and Cerus Sign New Agreement to Commercialize INTERCEPT Blood System, announcing and briefly describing the material terms of the agreement is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 2.02. Results of Operations and Financial Condition.**

On February 3, 2005, the Company announced its financial results for its fourth quarter and fiscal year ended December 31, 2004. A copy of the Company's press release, entitled Cerus Corporation Announces Fourth Quarter and Year-End Results, is furnished pursuant to Item 2.02 as Exhibit 99.2 hereto.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release, dated February 3, 2005, entitled Baxter and Cerus Sign New Agreement to Commercialize INTERCEPT Blood System.

99.2 Press Release, dated February 3, 2005, entitled Cerus Corporation Announces Fourth Quarter and Year-End Results.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CERUS CORPORATION**

Dated: February 3, 2005

By: /s/ William J. Dawson  
William J. Dawson  
Vice President, Finance and Chief Financial  
Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated February 3, 2005, entitled Baxter and Cerus Sign New Agreement to Commercialize INTERCEPT Blood System.
99.2	Press Release, dated February 3, 2005, entitled Cerus Corporation Announces Fourth Quarter and Year-End Results.